Atrium Therapeutics completes spin-off from Avidity; 15.5M shares distributed, trading begins Feb 27 under RNA

Atrium Therapeutics, Inc.

Avidity distributed 15,514,966 Atrium shares at a ratio of 1 share per 10 Avidity shares; holds no equity interest after.
Atrium shares expected to begin trading on Nasdaq under symbol RNA on February 27, 2026.
Registration statement declared effective and spin-off consummated on February 26, 2026.
Novartis acquisition of Avidity expected to close on February 27, 2026, subject to conditions.
Atrium focused on early-stage precision cardiology programs ATR-1086 (phospholamban) and ATR-1072 (PRKAG2 syndrome).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.